top of page

News
Search


Testavec appoints new Director to Drive business growth
DAVID LASKOW-POOLEY JOINS BOARD OF TESTAVEC LTD David Laskow- Pooley has joined the company to accelerate the commercialisation of the...
Aug 1, 2024


TestAVec researchers devise new protocols to generate high titre HIV-1 lentivirus vectors in a cost efficient and scalable method
TestAVec researchers, lead by CSO Professor Michael Themis, have devised new protocols for making high titre HIV-1 lentivirus particles...
Feb 1, 2024


Happy holidays from the TestAVec team
From all of us here at TestAVec, we wish you a happy holiday season and new year. Time to enjoy the festive period and go into 2024 to...
Dec 25, 2023


TestAVec and Vidiia accelerating DNA damage testing platform
TestAVec and Vidiia are working together to accelerate DiNARep to commercial testing. DiNARep identifies if patients are able to repair...
Dec 18, 2023


FDA cancer concern over CAR-T gene therapy
Recently, the US Food and Drug Administration (FDA) has expressed that it is investigating cases of blood cancer in CAR-T therapies....
Dec 15, 2023
bottom of page